Trial · NCT00503035
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
NCT00503035, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2023-02-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers. Trials, record NCT00503035. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00503035
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
- NCT number
- NCT00503035
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 51 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- Celecoxib, Colonoscopy Biopsy
- First posted
- 2007-07-18
- Last updated
- 2023-02-13
- Results first posted
- 2023-02-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 13-HODE Colonic Tissue Levels | Baseline to post 6 months of celecoxib treatment | 13-HODE colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues |
| Secondary | PGE2 Colonic Tissue Levels | at the baseline colonoscopy (or sigmoidoscopy in patients who had undergone colectomy) before the initiation of celecoxib, and the follow-up colonoscopy or sigmoidoscopy was performed after celecoxib treatment (month 6) | PGE2 colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 13-HODE Colonic Tissue Levels | Baseline to post 6 months of celecoxib treatment | ng/mg tissue protein | MEAN | |
| SECONDARY | PGE2 Colonic Tissue Levels | at the baseline colonoscopy (or sigmoidoscopy in patients who had undergone colectomy) before the initiation of celecoxib, and the follow-up colonoscopy or sigmoidoscopy was performed after celecoxib treatment (month 6) | ng/mg tissue protein | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 13-HODE Colonic Tissue Levels | Celecoxib | polyps before celecoxib treatment | 14.56 | Standard Deviation 9.93 | ng/mg tissue protein |
| 13-HODE Colonic Tissue Levels | Celecoxib | polyps after celecoxib treatment | 18.83 | Standard Deviation 14 | ng/mg tissue protein |
| 13-HODE Colonic Tissue Levels | Celecoxib | Normal: before celecoxib treatment | 23.02 | Standard Deviation 18.55 | ng/mg tissue protein |
| 13-HODE Colonic Tissue Levels | Celecoxib | Normal: after celecoxib treatment | 20.03 | Standard Deviation 11.7 | ng/mg tissue protein |
| PGE2 Colonic Tissue Levels | Celecoxib | Polyps: before celecoxib treatment | 14.71 | Standard Deviation 6.95 | ng/mg tissue protein |
| PGE2 Colonic Tissue Levels | Celecoxib | Polyps: after celecoxib treatment | 20.62 | Standard Deviation 10.48 | ng/mg tissue protein |
| PGE2 Colonic Tissue Levels | Celecoxib | Normal: before celecoxib treatment | 21.48 | Standard Deviation 14.32 | ng/mg tissue protein |
| PGE2 Colonic Tissue Levels | Celecoxib | Normal: after celecoxib treatment | 24.99 | Standard Deviation 18.25 | ng/mg tissue protein |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Celecoxib | 47 | |
| Overall Study | COMPLETED | Celecoxib | 27 | |
| Overall Study | NOT COMPLETED | Celecoxib | 20 |
Source ClinicalTrials.gov
Adverse events41
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Celecoxib | 5 | 32 | |
| other | Allergic Reaction | Skin and subcutaneous tissue disorders | Celecoxib | 2 | 32 | |
| other | Anorexia | Gastrointestinal disorders | Celecoxib | 1 | 32 | |
| other | Rectal bleeding | Gastrointestinal disorders | Celecoxib | 4 | 32 | |
| other | Blurred vision | Eye disorders | Celecoxib | 1 | 32 | |
| other | Bruising | Blood and lymphatic system disorders | Celecoxib | 2 | 32 | |
| other | Constipation | Gastrointestinal disorders | Celecoxib | 2 | 32 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Celecoxib | 2 | 32 | |
| other | Cramping | Gastrointestinal disorders | Celecoxib | 1 | 32 | |
| other | Diarrhea | Gastrointestinal disorders | Celecoxib | 1 | 32 |
1 to 10 of 41Source ClinicalTrials.gov
See all 41 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Celecoxib | 0 | 32 |
| Total, other adverse events | Celecoxib | 24 | 32 |
| Total, serious adverse events | Celecoxib | 2 | 32 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA106577 | 5-LOX-1 and Clinical Chemoprevention of Colon Tumors | SHUREIQI, IMAD | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 2005 to 2008 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00503035
GET https://conductscience.org/api/trials/v1/NCT00503035/events?page=2